Phio Pharmaceuticals Corp. PHIOW 深 沪
等待开盘 05-20 09:30:00 美东时间
0.0232
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.0232
- 总市值 10.63万
- 52周最高 1.16
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.006
- 委 比 0.00%
- 总股本 458.09万
- 历史最高 1.16
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.006
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Phio Pharma Q1 EPS $(0.34) Misses $(0.23) Estimate
Phio Pharma (NASDAQ:PHIO) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.23) by 47.83 percent. This is a 27.66 percent increase over losses of $(0.47) per share from the
05-08 04:51
Phio Pharma To Discuss Cancer Drug Progress In Upcoming Investor Chat, Highlights Early Results For Skin Cancer Treatment Ahead Of Event
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today
04-13 19:14
Phio Pharmaceuticals Establishes New At-the-Market Equity Program
Phio Pharmaceuticals ( ($PHIO) ) has provided an announcement. On April 8, 2026...
04-09 05:15
Phio signs U.S. cGMP manufacturing deal for PH-762 clinical, commercial supply
Phio signs U.S. cGMP manufacturing deal for PH-762 clinical, commercial supply Phio Pharmaceuticals signed a cGMP drug product manufacturing services agreement with a U.S. manufacturer to supply PH-762 for future clinical trials. Deal covers production of PH-762 for both clinical supply and commerci
03-30 19:03
Phio Pharmaceuticals reports 65% pathological response rate in Phase 1b trial of PH-762 for cutaneous squamous cell carcinoma
Phio Pharmaceuticals reports 65% pathological response rate in Phase 1b trial of PH-762 for cutaneous squamous cell carcinoma Phio said Phase 1b results from its escalating-dose study of intratumoral PH-762 (NCT 06014086) in cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma will
03-23 19:04
Phio Pharmaceuticals to Present at Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Phio Pharmaceuticals to Present at Renmark Financial Communications Live Virtual Non-Deal Roadshow Series Phio Pharmaceuticals Corp. will participate in Renmark Financial Communications’ live Virtual Non-Deal Roadshow Series with a live presentation and Q&A on Monday, March 9, 2026 at 10:00 a.m. EDT
03-05 20:03
Phio Pharmaceuticals boosts CEO Bitterman severance and target bonus terms
Phio Pharmaceuticals boosts CEO Bitterman severance and target bonus terms Phio Pharmaceuticals Corp. amended CEO Robert J. Bitterman’s employment agreement. The update raises his annual target bonus opportunity to 50% of base salary (from 40%) and provides 12 months of base-salary severance if he i
02-19 05:01
Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients
Phio Pharmaceuticals shares rise after Phase 1b data shows strong safety and tumor clearance for its PH-762 skin cancer drug, with FDA talks planned in 2026.
02-11 00:12
BUZZ-U.S. STOCKS ON THE MOVE-Zimmer Biomet, Datadog, Ecolab
BUZZ-U.S. STOCKS ON THE MOVE-Zimmer Biomet, Datadog, Ecolab Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500 and the Nasdaq edged lower on Tuesday, bogged down by decline
02-10 23:41
Phio Pharmaceuticals Reports Positive PH-762 Phase 1b Safety Results
Phio Pharmaceuticals ( ($PHIO) ) has shared an announcement. On February 10, 20...
02-10 20:59
